Arca
Skip to content
Tools
Tools

Hypocalcemia

Drug research and approvals for hypocalcemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 10 studies of hypocalcemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, and FDA has 2 approved and 1 open orphan designations naming it.

  • Recruiting worldwide: 10
  • Trials authorized in Canada: 1
  • FDA orphan approvals: 2
  • EU medicines: 0

Recruiting now

Newest posted first, of 10 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 2

Phase 3 2

Phase 2 3

How its trials ended

71 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 10 whose ending is known, 60% met their primary endpoint, 10% missed it and 30% stopped early.

  • Completed, result not reported2535%
  • Status unknown2028%
  • Ongoing1623%
  • Met its primary endpoint68%
  • Missed its primary endpoint11%
  • Stopped: lack of efficacy11%
  • Stopped: enrollment or feasibility11%
  • Stopped: other or unclear11%

Trials authorized in Canada

Newest first; search them all in Canada trials
AuthorizedTrialSponsorStatus
Nov 17, 2022Calibrate: a phase 3, randomized, open-label study evaluating the efficacy and safety of encaleret compared to standard of care in participants with autosomal…Encaleret (CLTX-305)Calcilytix Therapeutics IncOngoing

FDA orphan designations

Approved first, then open designations, newest first
Jan 23, 2015NatparaAn adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidismTakeda Pharmaceuticals U.S.A., Inc.Approved
Dec 23, 1987ParatharDiagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due…Rhone-Poulenc Rorer Pharmaceuticals, Inc.Approved
Nov 24, 2020Encaleret sulfateTreatment for autosomal dominant hypocalcemia (including ADH type 1 and ADH type 2)Calcilytix Therapeutics, Inc. a BridgeBio CompanyDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.